Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 297

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 297
---
 and inability to continue operations.

Significant
additional research and development activity, pre-clinical testing, and/or clinical testing Telomir-1 is required before we will have
a chance to achieve a viable product for licensing or commercialization. Our business currently depends entirely on the successful development,
regulatory approval, and licensing or commercialization of our product candidate, which may never occur.

Enforcement
of our licensed patent application or defense of any claims asserting invalidity of these patents is often subject to the control or
cooperation of our licensor. Legal action could be initiated against the owners of the intellectual property that we license and an adverse
outcome in such legal action could harm our business because it might prevent such companies or institutions from continuing to license
intellectual property that we may need to operate our business. In addition, such licensor may resolve such litigation in a way that
benefits it but adversely affects our ability to have freedom to operate to develop and commercialize Telomir-1.

21

We
may not be able to adequately protect our product candidates or our proprietary technology in the marketplace.

Our
success will depend, in part, on our ability to obtain patents, protect our trade secrets and operate without infringing on the proprietary
rights of others. We may rely upon a combination of patents, trade secret protection (i.e., know-how), trademarks, licenses, and confidentiality
agreements to protect the intellectual property of our product candidates. The strengths of patents in the pharmaceutical field involve
complex legal and scientific questions and can be uncertain. Where appropriate, we seek patent protection for certain aspects of our
products and technology. However, patent protection for naturally occurring compounds is exceedingly difficult to obtain, defend and
enforce. Filing, prosecuting and defending patents throughout the world would be prohibitively expensive, so our policy is to look to
patent technologies with commercial potential in jurisdictions with significant commercial opportunities. However, patent protection
may not be available for some of the products or technology we are developing. If we must spend significant time and money protecting,
defending, or enforcing our patents, designing around patents held by others or licensing, potentially for large fees, patents or other
proprietary rights held by others, our business, results of operations and financial condition may be harmed. We may not develop additional
proprietary products that are patentable.

The
patent positions of pharmaceutical products are complex and uncertain. Although we have sought and expect to continue to seek patent
protection for our product